These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27178257)

  • 1. Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis.
    Conrado DJ; Krishnaswami S; Shoji S; Kolluri S; Hey-Hadavi J; McCabe D; Rojo R; Tammara BK
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):325-41. PubMed ID: 27178257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
    Stock T; Fleishaker D; Wang X; Mukherjee A; Mebus C
    Int J Rheum Dis; 2017 Aug; 20(8):960-970. PubMed ID: 28328159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of Fosdagrocorat (PF-04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis.
    Weatherley B; McFadyen L; Tammara B
    Clin Transl Sci; 2018 Jan; 11(1):54-62. PubMed ID: 29106053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics.
    Shoji S; Suzuki A; Conrado DJ; Peterson MC; Hey-Hadavi J; McCabe D; Rojo R; Tammara BK
    CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):439-448. PubMed ID: 28556506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.
    Buttgereit F; Strand V; Lee EB; Simon-Campos A; McCabe D; Genet A; Tammara B; Rojo R; Hey-Hadavi J
    RMD Open; 2019; 5(1):e000889. PubMed ID: 31168411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study.
    Seymour MW; Kelly S; Beals CR; Malice MP; Bolognese JA; Dardzinski BJ; Cheng AS; Cummings CE; Smugar SS; McClinton C; Fox A; Dooley WM; Pitzalis C; Taylor PC
    Arthritis Res Ther; 2012 Sep; 14(5):R198. PubMed ID: 22972032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
    Toyoshima J; Kaibara A; Shibata M; Kaneko Y; Izutsu H; Nishimura T
    Pharmacol Res Perspect; 2021 May; 9(3):e00744. PubMed ID: 33929089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study.
    Amalraj A; Varma K; Jacob J; Divya C; Kunnumakkara AB; Stohs SJ; Gopi S
    J Med Food; 2017 Oct; 20(10):1022-1030. PubMed ID: 28850308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
    Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Van der Elst K; Meyfroidt S; Westhovens R;
    Arthritis Res Ther; 2015 Apr; 17(1):97. PubMed ID: 25889222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid receptor up-regulation in early rheumatoid arthritis treated with low dose prednisone or placebo.
    Huisman AM; Siewertsz van Everdingen AA; Wenting MJ; Lafeber F; van Reesema DR; Jacobs JW; Bijlsma JW
    Clin Exp Rheumatol; 2003; 21(2):217-20. PubMed ID: 12747278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
    Bickham K; Kivitz AJ; Mehta A; Frontera N; Shah S; Stryszak P; Popmihajlov Z; Peloso PM
    BMC Musculoskelet Disord; 2016 Aug; 17():331. PubMed ID: 27502582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of methotrexate effect on the acute-phase response in rheumatoid arthritis after 12-week treatment].
    Murav'ev IuV; Gridneva GI; Karateev DE; Luchikhina EL; Omonin IuL; Aleksandrova EN; Kashnikova LN; Glukhova SI; Nasonov EL
    Klin Med (Mosk); 2014; 92(3):59-63. PubMed ID: 25269199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
    Kremer JM; Emery P; Camp HS; Friedman A; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S; Keystone EC
    Arthritis Rheumatol; 2016 Dec; 68(12):2867-2877. PubMed ID: 27389975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
    Genovese MC; Smolen JS; Weinblatt ME; Burmester GR; Meerwein S; Camp HS; Wang L; Othman AA; Khan N; Pangan AL; Jungerwirth S
    Arthritis Rheumatol; 2016 Dec; 68(12):2857-2866. PubMed ID: 27390150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying Clinical Factors Associated With Low Disease Activity and Remission of Rheumatoid Arthritis During Pregnancy.
    Ince-Askan H; Hazes JMW; Dolhain RJEM
    Arthritis Care Res (Hoboken); 2017 Sep; 69(9):1297-1303. PubMed ID: 27813290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
    Huizinga TW; Batalov A; Stoilov R; Lloyd E; Wagner T; Saurigny D; Souberbielle B; Esfandiari E
    Arthritis Res Ther; 2017 Mar; 19(1):53. PubMed ID: 28274253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.